Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 12/20 | 0.35 |
| ▸ | MTOR | P42345 | 12/20 | 0.35 |
| ▸ | PDE2A | O00408 | 2/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | MAT2A | P31153 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.32 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25876309 | 0.90 | PIK3CA (0.36) | LRRK2PIK3CAMTORPDE2APIK3CD | |
| SCHEMBL25876233 | 0.89 | MAT2A (0.33) | LRRK2PDE2AMAT2AHSP90AA1HSP90B1 | |
| SCHEMBL25875942 | 0.89 | MAT2A (0.42) | LRRK2MAT2APDE4B | |
| SCHEMBL25875993 | 0.87 | MAT2A (0.33) | LRRK2PDE2AMAT2AHSP90AA1HSP90B1 | |
| SCHEMBL25876077 | 0.87 | MERTK (0.35) | LRRK2MAT2AHSP90AA1HSP90B1TRAP1 | |
| SCHEMBL25876275 | 0.87 | PDE1A (0.36) | LRRK2MAT2AHSP90AA1HSP90B1TRAP1 | |
| SCHEMBL25876041 | 0.86 | MAT2A (0.35) | LRRK2PDE2AMAT2AHSP90AA1HSP90B1 | |
| SCHEMBL25875863 | 0.83 | PDE2A (0.41) | PDE2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL25876131 | 0.82 | PDE9A (0.34) | PIK3CAMTOR | |
| SCHEMBL25875902 | 0.82 | DGAT1 (0.33) | MAT2AHSP90AA1HSP90B1TRAP1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | TYK MEDICINES, INC. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | TYK MEDICINES, INC. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | RET, ROR1, FGFR3 | LRRK2 181/4885PIK3CA 487/4885MTOR 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.